Skip to main content
letter
. 2016 Apr 28;114(11):e9. doi: 10.1038/bjc.2016.70

Figure 1.

Figure 1

Survival under second-line chemotherapy with gemcitabine + Nab-paclitaxel, according to first-line PFS. (A) PFS under second-line chemotherapy with gemcitabine+Nab-paclitaxel (PFS-2): RP patients vs low progressive patients. (B) OS under second-line chemotherapy with gemcitabine+Nab-paclitaxel (OS-2): RP patients vs low progressive patients.